“This Tiny, Unknown Biotech is About to Unleash Its ‘Holy Grail’ Drug”

Robert Morris is helming a biotech-focused stock newsletter that’s called Biotech Supertrader (modesty has no place in the world of newsletter promotions, of course), and I’ve never covered this letter before so I thought I ought to have a look at the latest teaser we’ve been asked about. Morris, incidentally, has been featured in our […]